A Next-Generation Treatment for Familial Hypercholesterolaemia

Time: 1:30 pm
day: Day One

Details:

  • Exploring a novel CRISPR-based gene editing approach to upregulate LDLR expression
  • Outlining the potential efficacy, safety and dosing benefits of avoiding PCSK9 knockouts
  • Explaining the benefits of proprietary novel nucleases for this treatment option

Speakers: